Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C79H129N27O22 |
Molecular Weight | 1809.0373 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC2=CC=CC=C2)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O
InChI
InChIKey=PULGYDLMFSFVBL-SMFNREODSA-N
InChI=1S/C79H129N27O22/c1-41(2)33-54(72(122)95-44(5)66(116)103-56(36-59(84)110)73(123)102-53(77(127)128)27-28-58(83)109)104-70(120)49(23-13-15-29-80)100-69(119)52(26-18-32-90-79(87)88)99-65(115)43(4)96-75(125)57(40-107)105-71(121)50(24-14-16-30-81)101-68(118)51(25-17-31-89-78(85)86)98-64(114)42(3)94-61(112)39-93-76(126)63(45(6)108)106-74(124)55(35-47-21-11-8-12-22-47)97-62(113)38-91-60(111)37-92-67(117)48(82)34-46-19-9-7-10-20-46/h7-12,19-22,41-45,48-57,63,107-108H,13-18,23-40,80-82H2,1-6H3,(H2,83,109)(H2,84,110)(H,91,111)(H,92,117)(H,93,126)(H,94,112)(H,95,122)(H,96,125)(H,97,113)(H,98,114)(H,99,115)(H,100,119)(H,101,118)(H,102,123)(H,103,116)(H,104,120)(H,105,121)(H,106,124)(H,127,128)(H4,85,86,89)(H4,87,88,90)/t42-,43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,63-/m0/s1
Orphanin FQ (OFQ, Nociceptin) is a recently discovered 17-amino acid neuropeptide that is structurally related to the opioid peptides but does not bind opioid receptors. OFQ
selectively binds its own receptor (OFQR), which is also
sequentially related to the opioid receptors, yet does not bind
opioid ligands. OFQ has been proposed to act as an anti-opioid peptide, but its widespread sites of action in the brain suggest that it may have more general functions. Nociceptin acts as an anxiolytic to attenuate behavioral responses to stress. In vivo experiments have demonstrated that Nociceptin modulates a variety of biological functions ranging from nociception to food intake, from memory processes to cardiovascular and renal functions, from spontaneous locomotor activity to gastrointestinal motility, from anxiety to the control of neurotransmitter release at peripheral and central sites. Nociceptin has being shown to directly inhibit an adaptive immune response, i.e., antibody formation, both in vitro and in vivo.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. | 1997 Nov |
|
Relationship between binding affinity and functional activity of nociceptin/orphanin FQ. | 1997 Oct |
|
Comparison of the effects of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors. | 1999 May |
|
Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)amide analogues. 1. In vitro studies. | 2002 Jun |
|
Orphanin FQ/nociceptin but not Ro 65-6570 inhibits the expression of cocaine-induced conditioned place preference. | 2002 May |
|
Distinct effects of nociceptin analogs on scopolamine-induced memory impairment in mice. | 2009 Jan 14 |
|
Orphanin FQ/nociceptin not only blocks but also reverses behavioral adaptive changes induced by repeated cocaine in mice. | 2010 Aug 1 |
|
Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine. | 2011 Oct 13 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11423087
Rats: Intrathecal (i.t.) administration of Nociceptin (0.2--20 nmoles) dose-dependently reversed mechanical allodynic-like behavior
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17206761
Suspension muscle strips test in vitro showed Nociceptin (OFQ) (10(-9)-10(-6) mol/L) concentration dependently caused an immediate tonic contraction in the isolated rat colon.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID60168933
Created by
admin on Sat Dec 16 08:25:55 GMT 2023 , Edited by admin on Sat Dec 16 08:25:55 GMT 2023
|
PRIMARY | |||
|
16131448
Created by
admin on Sat Dec 16 08:25:55 GMT 2023 , Edited by admin on Sat Dec 16 08:25:55 GMT 2023
|
PRIMARY | |||
|
170713-75-4
Created by
admin on Sat Dec 16 08:25:55 GMT 2023 , Edited by admin on Sat Dec 16 08:25:55 GMT 2023
|
PRIMARY | |||
|
7AYI9N34FF
Created by
admin on Sat Dec 16 08:25:55 GMT 2023 , Edited by admin on Sat Dec 16 08:25:55 GMT 2023
|
PRIMARY | |||
|
m8024
Created by
admin on Sat Dec 16 08:25:55 GMT 2023 , Edited by admin on Sat Dec 16 08:25:55 GMT 2023
|
PRIMARY | Merck Index | ||
|
80266
Created by
admin on Sat Dec 16 08:25:55 GMT 2023 , Edited by admin on Sat Dec 16 08:25:55 GMT 2023
|
PRIMARY | |||
|
Nociceptin
Created by
admin on Sat Dec 16 08:25:55 GMT 2023 , Edited by admin on Sat Dec 16 08:25:55 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD